Peptide Therapeutics Market, By Product Type (Branded Peptide and Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Feb 2023

Code : CMI1837

Pages :184

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Peptide Therapeutics Market- Drivers

Increasing research and development activity

Peptide therapeutics is used in research and development of new drugs and therapies. Thus, increasing research and development activity by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in August 2022, an article published in Biomedicines, an open access journal, stated the use of peptide-based drug development for the development of different treatment options for cancer.

Increasing prevalence of cancer

Peptide therapeutics technology is used for the treatment of cancer and thus increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, in December 2022, according to an article published by National Centre for Biotechnology Information (NCBI), estimated number of incident cases of cancer, in India, for the year 2022 was found to be 14, 61,427. In India, one in nine people are likely to develop cancer in his/her lifetime. Lung and breast cancers were the leading sites of cancer in males and females, respectively.

Global Peptide Therapeutics Market: Restraint

Disadvantages of peptide therapeutics

The major factors that can hamper growth of the global peptide therapeutics market over the forecast period include false positive and negative responses, Major Histocompatibility Complex (MHC) restrictions, low immunogenic potency, and need for adjuvant such as such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate, etc. For instance, in March 2022, a report published by Springer Nature, a scientific journal, stated the major challenges of using peptide as targeted therapeutic agents, such as disproportionate physical and chemical properties, that must be changed to be in line with therapeutic goals and peptides limited aﬃnity for cellular targets, which necessitates peptide structural alterations.